New data are suggesting that deciphering the genomic diversity and evolution of tumors may provide a basis for identifying new targets and designing improved personalized medicine strategies.
It may soon be possible to get rid of the “one-size-fits-all” approach when it comes to radiation therapy.
Researchers are reporting in the journal Cancer Research that they have identified a biomarker enzyme associated with aggressive glioma brain tumors. In addition, they have demonstrated potent efficacy in a mouse model of glioma for a small molecule inhibitor they recently developed.
Investigators at the Dana-Farber Cancer Institute in Boston for the first time have identified unique genomic changes that may be integral to testicular cancer.
Scientists have found a way to detect earlier if Merkel cell carcinoma (MCC) is recurring in patients. They have published a paper in the journal Cancer demonstrating how an immune system marker may be able to outperform and supplement imaging studies for recurrence of MCC.
Newer cancer drugs are being approved on the basis of shorter studies and on outcomes that might not predict living longer or feeling better.
Researchers from X4 Pharmaceuticals in Cambridge, Mass., have been developing novel CXCR4 inhibitor drugs to improve immune cell trafficking and increase the ability for T cells to track and destroy cancer.
The US Food and Drug Administration is granting ponatinib (Iclusig) full approval for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia for whom no other tyrosine kinase inhibitor therapy is indicated.
While determining the genetic makeup of a patient’s tumor is a critical tool for precision cancer medicine, there are still several challenges and unanswered questions about large-scale clinical application of the methods.
A high-risk subtype of acute lymphoblastic leukemia first identified in children appears to be highly prevalent in adults with ALL and is associated with a poor outcome.